Innocoll, which develops absorbable collagen drugs to treat pain, foot infections and adhesions, raised $59 million by offering 6.5 million ADSs (upsized from 5.4 million) at $9, below the range of $13 to $15. Insiders were expected to purchase $27 million (46% of the deal). Innocoll plans to list on the NASDAQ under the symbol INNL. Innocoll initially filed confidentially on 3/26/2014. Piper Jaffray and Stifel acted as joint bookrunners on the deal.
